EBIA members collectively sign Sleep Manifesto to raise public sleep awareness

The quality of sleep is under pressure: while adults need an average of seven to eight hours of sleep for optimum health and well-being, more than 1 out of 3 people get less than six hours of sleep every night. This can have major consequences, for example fatigue is the main cause of driver errors in 20% of road accidents. Moreover, insufficient sleep leads to chronic health problems, such as diabetes, obesity, heart diseases and strokes. In order to address these major issues and to raise awareness about the importance of a good quality of sleep, Beter Bed Holding’s CEO, John Kruijssen, made an appeal to the industry to co-sign the Sleep Manifesto at the 23rd EBIA General Assembly in Copenhagen.

EBIA - the European Bedding Industries’ Association - represents the interests of European mattress producers and suppliers. Mattress producers, innerspring companies, textile industries, as well as PU foam and latex suppliers and representatives of the chemical industry from all over Europe were present at the EBIA General Assembly. John Kruijssen, CEO of Beter Bed Holding, appealed to the community to sign the Sleep Manifesto, referring to results of scientific research on sleep that has increased knowledge about sleep dramatically in the past years. “What if we could address prevention and improve the quality of sleep and therefore lower overall healthcare costs and increase productivity? The quality of sleep has a significant impact on productivity. In the Netherlands alone, productivity loss is estimated to equate to 1.5% to 3% of GDP per year, which is equivalent somewhere between 13 and 26 billion euro,” stated Kruijssen. “There are a lot of other major issues that we, as the European industry, need to address in order for consumers to sleep better, and therefore, live healthier, or I should say, sleep better, live better.”

Wake-up call With the aim of helping consumers to get a better night's rest, Beter Bed launched the Sleep Manifesto earlier this month, with the aim to raise sleep awareness and improve sleep. Sleep deprivation can affect our body, brain and life expectancy. Matthew Walker, an internationally renowned sleep scientist and author of 'Why We Sleep' and TEDx speaker with more than 16 million views, recognised this problem and supported the Manifesto with his first signature. “If 50 to 60% of the entire population were to get more sleep, it would save millions of euros in healthcare spending,” said Walker while signing the Manifesto.

At the EBIA, Kruijssen called on the industry to follow in Walker’s footsteps in order to put the importance of better sleep on the agenda. The aim is to encourage better sleep behaviour and provide more information to address this social problem. “Because of the lack of awareness of the benefits of healthy sleep, multisectoral public health campaigns are needed to educate the public about the importance of sleep and the consequences of insufficient sleep,” Kruijssen stated. “Our mission is simple. We believe that the better we sleep, the happier, healthier and more productive we are. And we won’t rest until everyone gets the high-quality sleep they deserve”.

Beter Bed believes and promises that everyone can sleep better and does everything to fulfil this promise to increase public awareness of the importance of sleep, through its own platforms, but also through ambassadors and its network of specialists and scientists. Beter Bed has developed a set of innovative solutions, such as Beter Slapen ID, a measuring system that allows it to offer customers objective data-driven sleep advice. All with the aim of providing our employees and consumers with information on how to sleep better.

About Beter Bed Holding Beter Bed Holding (BBH) is the Netherlands’ leading sleep specialist in retail, wholesale and B2B. Our mission is simple. We believe that the better we sleep, the happier, healthier and more productive we are. And we won’t rest until everyone gets the high-quality sleep they deserve. Listed on Euronext Amsterdam, BBH operates the successful retail brands Beter Bed, Beddenreus, the new subscription brand Leazzzy and the digital organisation LUNEXT. In addition, through its subsidiary DBC International, BBH has a wholesale business in branded products in the bedroom furnishings sector, which includes the well-known international brand M line.

With 4 distribution centres, a fleet of 80 vehicles, 134 stores, a fast-growing online presence, and a wholesale company our team of over 1,000 dedicated employees generated € 214.2 million revenue in 2021.

Providing expert sleep advice is at the very heart of our strategy, and thanks to our revolutionary ‘Beter Slapen ID’ tool, our sleep consultants help customers to get the perfect night’s sleep. BBH is proud that M line is the official sleep supplier of AFC Ajax, TeamNL, Jumbo-Visma, NOC*NSF and the KNVB.

For more information Press enquiries: Uneke Dekkers / CFF Communications T +31 (0)20 575 4010 or M +31 (0)6 50261626 E uneke.dekkers@cffcommunications.nl

Please click on the link under attachments for the PDF version of the press release.

Press photos can be downloaded here.

UBS's Colin Bristow raised his rating on the stock to Buy from Neutral, saying Well Street's expectations for sales of Mounjaro are too low.

The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.

This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.

Shares of Spectrum Pharmaceuticals Inc. were down 22.0% in premarket trading on Friday, the day after a Food and Drug Administration committee voted 9-4 that the benefits of the company's experimental lung-cancer drug do not outweigh the risks. The FDA is not required to follow the committee's advice when deciding when to approve a new drug but often does. The regulator is expected to make its decision on or before Nov. 24. Spectrum on Friday also announced a five-year debt financing plan with S

Shares of Bristol Myers Squibb (NYSE: BMY) were bouncing 3.4% higher as of 3:31 p.m. ET on Thursday after slipping a little earlier this week. Instead, today's move appeared to be the result of investors seeking relatively safe stocks as the Nasdaq Composite index and Russell 2000 small-cap index fell. Bristol Myers Squibb has seemed to be sort of a safe haven for investors throughout much of 2022.

Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.

The social media giant’s head of community operations apologised at the inquest into the teenager’s death on Thursday.

Eli Lilly's blockbuster potential diabetes drug Mounjaro is "de-risked and transformative," an analyst said Thursday as he updated LLY stock.

Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.

The bear market hasn't dragged down Axsome Therapeutics (NASDAQ: AXSM). The biotech company specializes in treating central nervous system conditions. And it's been on a roll with good news -- and share performance -- in recent weeks.

OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that Dr. Philippe Genereux, Director of the Structural Heart Program at Morristown Medical Center in New Jersey, and his team, performed the first use of SavvyWire in a transcatheter aortic valve replacement (TAVR) procedure in the United States.

Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.

Shares of Eli Lilly & Co. Inc. gained 2.5% in premarket trading on Thursday after UBS upgraded the stock to buy from neutral, saying Mounjaro, the company's newly approved Type 2 diabetes drug, could be "the biggest drug ever." UBS analysts predict peak sales of $25 billion if the therapy is also approved as a treatment for weight management in people with obesity. "Tirzepatide's robust efficacy in both obesity and [Type 2 diabetes] should drive sales into a range that we believe could see this

A big question with the new COVID-19 vaccine: Can you mix brands? Here is what experts say

‘I happen to be a practising Roman Catholic. My church doesn’t even make that argument now,’ president says of abortion bans

AngioDynamics took a risk when it spent $66 million to acquire new laser technology that had yet to hit the market. Three years later, that bet is starting to pay off.

DBV Technologies (DVBT) announces partial hold on phase III study of modified Viaskin Peanut 250 ??g patch, VITESSE, by the FDA. Stock declines.

Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?

Harriet Corr, seven, is regaining her strength after enduring years of coughing fits and a weakened immune system

Healthcare exchange-traded funds (ETFs) invest in a basket of stocks of companies that provide medical services, develop medical equipment or drugs, offer medical insurance, or facilitate the provision of healthcare to patients.